Advanced Melanoma

Oncology·MeSH: Melanoma

Prevalence

75.0 / 100K

Incidence

23.0 / 100K/yr

14 drugs in development·7 companies·14 clinical trials

Drug Pipeline by Phase

Approved(2)

Drug	Company
COTELLIC	EXELIXIS, INC. (EXEL)
COTELLIC (cobimetinib)	EXELIXIS, INC. (EXEL)

Phase 3(4)

Phase 2(6)

Drug	Company
Autogene cevumeran	BioNTech SE (BNTX)
Infusion of HS-IT101 Injection	PTC THERAPEUTICS, INC. (PTCT)
Investigator's selection of appropriate chemotherapy regimen	PTC THERAPEUTICS, INC. (PTCT)
Lymphodepletion Conditioning	Merus N.V. (MRUS)
Lymphodepletion Conditioning	PTC THERAPEUTICS, INC. (PTCT)
rp1	Replimune Group, Inc. (REPL)

Phase 1(1)

Drug	Company
brenetafusp	Immunocore Holdings plc (IMCR)

Phase 2/Phase 3(1)

Drug	Company
eik1001	Eikon Therapeutics Inc. (EIKN)

BioSniper tracks 14 drugs in development for Advanced Melanoma across 7 companies.

There are 14 clinical trials targeting Advanced Melanoma tracked by BioSniper.

The estimated prevalence of Advanced Melanoma is approximately 75.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.